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Abstract
Background Under physiological conditions, the melano-
cortin system is a crucial part of the complex network
regulating food intake and energy expenditure. In patho-
logical states, like cachexia, these two parameters are
deregulated, i.e., food intake is decreased and energy
expenditure is increased—a vicious combination leading
to catabolism. Agouti-related protein (AgRP), the endoge-
nous antagonist at the melanocortin-4 receptor (MC-4R),
was found to increase food intake and to reduce energy
expenditure. This qualifies MC-4R blockade as an attrac-
tive mode of action for the treatment of cachexia. Based on
this rationale, a novel series of small-molecule MC-4R
antagonists was designed, from which the orally active
compound BL-6020/979 (formerly known as SNT207979)
emerged as the first promising development candidate
showing encouraging pre-clinical efficacy and safety
properties which are presented here.
Methods and results BL-6020/979 is an orally available,
selective and potent MC-4R antagonist with a drug-like
profile. It increased food intake and decreased energy
expenditure in healthy wild-type but not in MC-4R
deficient mice. More importantly, it ameliorated cachexia-
like symptoms in the murine C26 adenocarcinoma model;
with an effect on body mass and body composition and on
the expression of catabolic genes. Moreover, BL-6020/979
showed antidepressant-like properties in the chronic mild
stress model in rats and exhibits a favorable safety profile.
Conclusion The properties of BL-6020/979 demonstrated
in animal models and presented here make it a promising
candidate suitable for further development towards a first-
in-class treatment option for cachexia that potentially opens
up the opportunity to treat two hallmarks of the disease, i.e.,
decreased food intake and increased energy expenditure,
with one drug.
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1 Introduction
Cachexia is a complex wasting syndrome in chronically ill
patients that involuntarily lose more than 5% body mass
within 12 months or have a body mass index below 20 kg/m2,
and in addition exhibit at least three out of the following five
symptoms: anorexia, decreased muscle strength, fatigue, low
fat-free mass index or increased markers for inflammation
[1]. It is a highly prevalent co-morbidity that is associated
with a progressively decreasing quality of life and a predictor
of poor survival. It is extremely common in cancer patients.
Up to 80% of these patients develop cachexia and in more
than 20% of patients it is causal for their death [2, 3].
The pathological changes leading to cachexia are reduced
energy intake and at the same time an increase in resting energy
expenditure [4]. This vicious combination is responsible for
an accelerated catabolism [5]. So far, the mechanisms
underlying these changes are not well understood. Neverthe-
less, it has been proposed that cytokines might be key factors
for its genesis [6]. They are linked to increased energy
expenditure [7], decreased food intake [8], and the depletion
of skeletal muscle [9]. Mechanistically, it has been established
that cytokines can alter energy balance via the regulation of
pro-opiomelanocortin (POMC) expression [2]. Amongst
others, α-melanocyte stimulating hormone (α-MSH), a 13
amino acid peptide with appetite-inhibiting effects [10, 11] is
a cleavage product of POMC. The most prominent target
receptor for α-MSH to exert these anorexic effects is the
melanocortin-4 receptor (MC-4R).
Through blockade of the same receptor, however, the
exact opposite effects can be elicited. Agouti-related protein
(AgRP) is an endogenous antagonist at the MC-4R and has
been shown to increase food intake and reduce energy
expenditure [12–15]. This led to the hypothesis that the
MC-4R is a promising target to tackle these disastrous
maladaptations of cachexia [16]. Indeed, it has been
demonstrated in a number of rodent studies that interruption
of the MC-4R signaling pathway has the potential to
ameliorate cancer cachexia [17–19], and it has been
suggested that blockade of this pathway could eventually
be the key to treating the progression of cachexia [20, 21].
Besides cancer cachexia, MC-4R antagonism might be a
mechanism that could be exploited as treatment of
additional cancer symptoms such as anxiety and depression
[22].
Recently, we have introduced two novel non-peptidic,
orally active MC-4 receptor antagonists that increase food
intake in healthy animals and ameliorate cancer cachexia in
a rodent model [23]. Unfortunately, these early compounds
do not yet exhibit an overall favorable and safe profile that
would allow for further development into the clinic.
Moreover, it has not been shown if they decrease energy
expenditure, which would be predicted by the anticipated
mechanism of action. In fact, for our earlier compounds, no
in vivo evidence for the postulated MC-4R dependent
mechanism of action is available [23]. Unpredicted off-
target effects of these compounds could potentially be
responsible for the beneficial effects of these compounds in
the C26 cancer cachexia model.
Here we describe the discovery and characterization of
BL-6020/979 (formerly known as SNT207979) as the
results of a major effort to identify selective, potent and
orally active MC-4 receptor antagonists. Importantly, its
general pharmacological properties, tolerability and safety
were acceptable, and BL-6020/979 increased food intake in
healthy fed animals and was effective in the C26 cancer
cachexia model. In addition, BL-6020/979 did indeed lower
energy expenditure as previously hypothesized [23]. This
effect was absent in MC-4R deficient animals, thus strongly
suggesting a mechanism of action as predicted from the in
vitro data. Taken together, these results show the high
potential of BL-6020/979 for further development towards
a first-in-class treatment of cachexia.
2 Animals, materials, and methods
BL-6020/979 was designed and synthesized as SNT207979
in the Medicinal Chemistry Department at Santhera
Pharmaceuticals (Switzerland) Ltd. All animal experiments
were approved by the local authorities (Animal Care and
Use Committees of Oregon Health and Science University,
Portland, USA; Kantonales Verterinäramt Baselland,
Liestal, Switzerland (BL246, BL356); Bioethical Commit-
tee of the Institute of Pharmacology, Polish Academy of
Sciences, Kraków, Poland) and were in accordance with
international guidelines [24]. If not otherwise stated all
animals were held under standard laboratory conditions
(12 h light per day, 22±2°C, 40–60% humidity) with food
and water available ad libitum.
2.1 Pharmacology, safety and toxicology profile
of BL-6020/979
The specificity of BL-6020/979 was tested by studying in
vitro binding to human MC-4 receptors as well as closely
related human MC-3 and MC-5 receptors. An assay based
on fluorescence polarization in membrane suspensions
prepared from stably transfected HEK293 cells was used.
Furthermore, binding to human MC-1R and a standard
panel of 71 receptors, ion channels and transporters was
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measured at a concentration of 10 μM using a radio-ligand
binding assay. BL-6020/979 was tested in an in vitro whole
cell patch-clamp assay to determine inhibition of human
ether-a-go-go related gene (hERG) tail currents in stably
transfected HEK293 cells. Inhibition curves were con-
structed based on the results from three test concentrations
(0.1, 1.0, and 10 μM) and the IC50 was determined and
averaged. Assays were in accordance with international
safety guidelines published by the FDA as S7B of the
International Conference on Harmonisation of Technical
Requirements for Registration of Pharmaceuticals for
Human Use. The potential of BL-6020/979 to interact with
a standard in vitro panel of 41 enzymes, comprising
proteases, esterases, kinases, phosphatases, oxidases, and
transferases was tested at a concentration of 10 μM.
Another safety parameter that has to be considered in
drug development is the potential for undesired drug–drug
interaction. In particular, induction or inhibition of the
cytochrome P450 (CYP) isoforms is important in this
context [25]. Thus, the inhibition potential of BL-6020/979
for the major human CYP isoforms CYP1A2, CYP2C9,
CYP2C19, CYP2D6, and CYP3A4 was tested in incuba-
tions of human liver microsomes in the presence of
isoform-specific probe substrates as previously described
[26]. The potential of BL-6020/979 to induce CYP3A4 was
assessed in human hepatocytes from three individual
donors using midazolam as a probe substrate as described
[27].
The cytotoxic potential of BL-6020/979 was investigated
in HepG2 hepatoblastoma cells [28] measuring metabolic
activity of living cells using the WST-1 cell proliferation
reagent (Roche Diagnostics, CH). For a standard assay,
HepG2 cells were seeded into a 96-well micro-plate and
maintained in culture for 24 h. Then, they were exposed to
the test compound over a range of eight concentrations for
another 24 h until they were finally incubated with WST-1
for 30 min before measuring the absorbance of the
formazan dye formed. The TC50 (Toxic Concentration
50%) is defined as the concentration of tested compound
required to reduce the absorbance by 50% relative to the
control culture.
Genotoxicity was studied in vitro using automated Ames
tests in two bacterial strains (TA98 and TA100), both with
and without S9 fraction as described elsewhere [29].
The clastogenic and/or aneugenic potential of BL-6020/
979 was tested in vivo in 4-week-old male (n=18) and 6-
week-old female (n=18) CD-1 mice (Charles River, UK).
The dose of BL-6020/979 was determined as maximal
tolerated dose in a pre-study with a separate set of animals
as 750 mg/kg and 625 mg/kg BL-6020/979 p.o. in males
and females. Study animals were dosed daily for two
subsequent days with BL-6020/979 or vehicle alone (0.5%
carboxymethylcellulose). A third group of animals received
a single injection of 4 mg/kg Mitomycin C (a compound
with known clastogenic properties) i.p. on the second day
which served as a positive control for the assay. On the
third day, bone marrow was harvested, smears prepared and
microscopically scored for developing (polychromatic) and
mature (normochromatic) erythrocytes.
Seven day repeated dose toxicity studies were carried out
in mice and rats. Forty-eight mice of the Crl:CD-1 strain
were divided into four groups (6 males and 6 females per
group), and 50 Crl:WI (HAN) rats were divided into five
groups (5 males and 5 females per group). Mice and rats
were dosed by oral gavage for up to 7 days at dose levels of
200, 300, or 500 mg/kg/day, and at 100, 200, 300, or
500 mg/kg/day, respectively. Control animals received the
vehicle (0.5% carboxymethlycellulose) only. Standard
toxicity parameters were recorded during the study. Ten
selected organs were weighed and histopathology was
carried out.
Lastly, pharmacokinetic studies were performed. Plasma
protein binding is of relevance for the interpretation of
these studies. Plasma protein binding was determined by
equilibrium dialysis in 10% mouse, rat, dog and human
plasma at a concentration of 5 μM BL-6020/979 as
described elsewhere [30]. Brain penetration and oral
bioavailability of BL-6020/979 was evaluated in male
CD-1 mice and Sprague–Dawley rats after an oral dose of
50 mg/kg (in 5 ml/kg 10% hydroxypropyl-β-cyclodextrin
in 100 mM NaCl solution, n=3 per time point) as
previously described [23]. In addition, fasted male Beagle
dogs were dosed orally at 10 mg/kg (n=3). Brain and
plasma samples were analyzed by HPLC followed by mass
spectrometry (MS/MS). Brain/plasma ratios were then
calculated based on the area under the curve, and in rodents
integrity of the blood–brain barrier was determined by
co-dosing with Atenolol (absence of Atenolol indicated that
the blood–brain barrier was intact).
All in vitro assays except those for MC-3, MC-4, and
MC-5 receptors, which were established at Santhera,
hERG, which was performed by bSys (Witterswil,
Switzerland) and CYP inhibition and plasma protein
binding, which was performed by Cyprotex (UK), were
performed by MDS (Taiwan) or Cerep (France).
2.2 Food intake studies in healthy wild-type mice
Light-phase food intake experiments were conducted as
previously described [23]. In short, efficacy was demonstrated
following a single subcutaneous administration of 20 mg/kg
BL-6020/979 using 6-week-old female NMRI mice. There-
after, an oral dose–response curve was generated (vehicle, 10,
50, or 100 mg/kg) in NMRI mice housed in triplets dosed 3 h
after lights on. Just before and 4 h after administration, the
food hopper weight of each triplet, as well as the animals’
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individual body mass, was recorded. The measured values
from each cage were normalized to 100 g body mass.
2.3 Oxygen and food consumption studies in MC-4R
deficient mice
Six- to eight-week-old male C57BL/6J (wild-type) and
littermate MC4-R−/− mice from MC-4R+/− breeding pairs at
Oregon Health and Science University (Portland, USA) [31]
were used for food intake and energy expenditure experi-
ments. The strain had previously been backcrossed onto the
C57BL/6J background for more than ten generations. For
oxygen consumption experiments, mice were maintained in a
12/12 h light/dark cycle with ad libitum access to food
(Powdered Laboratory Rodent Diet, Purina 5001; PMI
Nutrition International, St. Louis, USA) and water. The
administration of BL-6020/979 or vehicle occurred either at
onset of light phase (daytime) or on a different day at onset
of dark phase (nighttime) and food and gas exchange
parameters were recorded for the following 4 and 8 h,
respectively (n=10 per group). Oxygen consumption (VO2)
and carbon dioxide production (VCO2) were simultaneously
determined by indirect calorimetry (Oxymax, Columbus
Instruments, Columbus, USA), while animals were housed
in separate chambers at 24±1°C. Mice were first acclimatized
to the chambers for 4 days. Measurements were recorded for
4–8 h at the start of the light cycle (08.00–16.00 h) or at the
start of the dark cycle (20.00–04.00 h). Parameters were
recorded approximately every 3 min with the room air
reference taken every 30 min. Basal oxygen consumption
was determined for individual mice as the average of the
lowest plateau regions corresponding to inactive periods.
For food intake experiments, animals were individually
housed for a minimum of 1 week prior to starting each
experiment. Animalswere habituated for a minimum of 4 days
to eating powdered chow (Purina 5001) from containers
designed to minimize spill and contamination of the remain-
ing food. On each day before dosing, the mean body weight of
each treatment group was determined. To calculate the
concentration needed for treatment groups, the dose, the mean
body weight, and the solution volume of gavage were
considered. Vehicle (10% hydroxypropyl-β-cyclodextrin in
100 mM saline) and working solutions of compound were
prepared daily before dosing. Eachmouse received the gavage
volume calculated as 1% of body mass. After weighing mice
and food, gavage was performed at the start of the study
interval using animal feeding needles (Popper and Sons, Inc.,
New Hyde Park, Japan).
2.4 C26 adenocarcinoma-induced cachexia model
The C26 colon adenocarcinoma model was used as
previously described [23]. In summary, 6-week-old male
BALB/c received unilateral subcutaneous injections of
approximately 1×106 C26 cells in phosphate-buffered saline
(PBS) or PBS only (n=9 per group). Starting on the next day
(day 1), animals were treated with 30 mg/kg BL-6020/979
p.o. or vehicle once daily. Wellbeing of the animal, tumor
growth, food intake and body mass were recorded daily.
Lean and fat mass of each animal were determined by MRI
relaxometry (EchoMRI-500, Echo Medical Systems, Hous-
ton, USA) on the day of inoculation (day 0) and at the end of
the experiment after removal of the tumor (day 15).
Furthermore, tissue samples of the gastrocnemius were
frozen on dry ice and stored at −80°C for RNA extraction
and subsequent gene expression analysis. Total RNA was
extracted using the RNeasy Fibrous Tissue Mini Kit (Qiagen,
Hombrechtikon, Switzerland). The initial homogenization
step was carried out using the gentleMACS™ M Tubes
(Miltenyi Biotec, Bergisch Gladbach, Germany). One
microgram of total RNA was reverse transcribed into cDNA
using the QuantiTect Rev. Transcription Kit (Qiagen,
Hombrechtikon, Switzerland). Quantitative real-time PCR
was carried out on the LightCycler® 480 System (Roche,
Rotkreuz, Switzerland) using the LightCycler® 480 SYBR
Green I Master (Roche, Rotkreuz, Switzerland). The
following primer pairs have been used for the target genes:
Atrogin-1 fwd AAGCGTTTGATCTTGTCTGA and rev
TGCTCTCTTCTTGGGTAACA; Pgc1beta fwd CCTACC
CACAAGGACAGCAT and rev ACCTTCCAGAG
CAGTCTCCA. And gapdh was used for standardization
(Primers: fwd ATTGTCAGCAATGCATCCTG and rev ATG
GACTGTGGTCATGAGCC).
2.5 Chronic mild stress model in rats
The chronic mild stress model was used as described
elsewhere [32]. In short, male Wistar rats (Charles River,
Germany; 90–100 g at delivery) were first trained to
consume a 1% sucrose solution, and sucrose consumption
was monitored at weekly intervals throughout the whole
experiment. On the basis of their sucrose intakes in the final
baseline test, animals were divided into two matched
groups. One group of animals was subjected to the chronic
mild stress procedure (two periods of food or water
deprivation, two periods of 45° cage tilt, two periods of
intermittent illumination, two periods of soiled cage, one
period of paired housing, two periods of low intensity
stroboscopic illumination, and three periods of no stress;
with a duration of 10–14 h for each period) for seven
consecutive weeks. The other group of animals (controls)
was held in a separate room with no contact to the stressed
rats and no exposure to stress conditions. On the basis of
their sucrose intakes in the initial 2 weeks of stress, both
stressed and control groups were each divided further into
matched subgroups (n=8), and for subsequent 5 weeks
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they received once daily administration of vehicle
(10% hydroxypropy-β-cyclodextrin in 100 mM saline,
p.o., 1 ml/kg), BL-6020/979 (p.o., 10 mg/kg) or imipramine
(i.p., 10 mg/kg) as the reference treatment.
2.6 Statistics
Multiple (repeated measures) analysis of variance (ANOVA)
with Dunnett’s or Bonferroni post hoc test where applicable
was used in all group comparisons; with the exception of gene
expression analysis where the non-parametric H-test was
used, and the survival analysis to compare numbers of
cachectic animals where the log-rank Mantel–Cox test was
used. All tests were carried out two-tailed with α=0.05 using
GraphPad Prism (GraphPad Software, CA, USA). All results
are given as means±SEM except gene expression data,
which are presented as median and interquartile range.
3 Results
3.1 Pharmacology and safety profile of BL-6020/979
In vitro binding of BL-6020/979 to the MC-4 receptor
followed a sigmoidal dose–response. The calculated
average IC50 was 19 nM. Binding of BL-6020/979 to
the MC-3 and MC-5 receptors resulted in IC50 values of
2.7 μM and 0.89 μM, respectively. No significant binding
was observed at the MC-1R at a test concentration of
10 μM. The resulting selectivity for the MC-4R over the
MC-3R was 140-fold and over MC-5R 50-fold. Selectivity
over the MC-1R was estimated to be >10,000-fold, based
on the binding result at 10 μM.
An MC-4R membrane agonist assay of BL-6020/979
measuring stimulation of cAMP production revealed that
the compound has no significant agonistic activity up to the
maximal test concentration of 100 μM. Schild plot analysis
of BL-6020/979 showed a regression slope significantly
less than 1, which might indicate that the antagonism is not
strictly competitive. The calculated KB of BL-6020/979 was
39 nM, corresponding to a pA2 value of 7.4.
Among all 71 receptor, transporter and ion channel off-
targets in the tested panel, no significant interaction was
found. In a patch-clamp assay, BL-6020/979 exhibited an
average IC50 of 4.6 μM at the IKr/hERG channel, indicating
that the compound was a weak inhibitor of this channel in
vitro. Moreover, BL-6020/979, at a concentration of
10 μM, did not significantly inhibit a range of 41 enzymes,
indicating the very low propensity of the compound
towards enzyme inhibition.
In vitro toxicology showed a favorable profile for
BL-6020/979. It exhibited a TC50 value of 93 μM,
indicating low cytotoxic potential. The same is true for
the lack of mutagenic potential as shown in a negative
AMES test. Furthermore, there was no change in frequency
in micro-nucleated cells in vivo in male mice at doses up to
750 mg/kg and females up to 625 mg/kg compared to
negative control animals and no evidence of bone marrow
toxicity following oral treatment with BL-6020/979 thereby
confirming that there is no evidence for clastogenic or
aneugenic effects of the compound.
In exploratory tolerability studies that were aimed at
determining suitable doses for longer term toxicity studies
in mice and rats, BL-6020/979 was administered once daily
by oral gavage to both species for 7 days. In mice, doses of
up to 500 mg/kg BL-6020/979 were well tolerated in
females and males and no adverse effects were found in the
post mortem analysis. In rats at necropsy, distension of the
gastro-intestinal tract of was observed at 500 mg/kg/day.
Consequently, in rats treated for 7 days with BL-6020/979,
the NOAEL was considered to be 300 mg/kg/day.
The potential for drug–drug interaction was explored in
CYP inhibition and induction assays. BL-6020/979 did not
inhibit CYP1A up to the highest test concentration of
25 μM. For CYP2C9, CYP2C19, and CYP2D6, interfer-
ence of the compound with the detection method of the
assay was observed at 25 μM and precluded assessment at
this concentration. However, no inhibition of these CYPs
was measured at a test concentration of 5 μM. Accordingly,
the IC50 for these isoforms were set >5 μM. In the case of
CYP3A4, the same interference occurred at a compound
concentration of 25 μM, but here 31% inhibition was
measured at a test concentration of 5 μM yielding an
estimated IC50 for CYP3A4 of 5–10 μM.
In human hepatocytes, no significant induction was
apparent at 0.1 μM. The largest extent of induction was
measured at a test concentration of 1 μM and amounted to
5-fold or 18% of the positive control response (which gave a
25-fold induction of CYP3A4 activity). However, at the
highest test concentration of 10 μM the observed induction
wasmerely 2-fold, corresponding to 7%of the positive control.
Lastly, the pharmacokinetic properties were assayed.
BL-6020/979 reaches the brain in mice and rats after oral
administration of 50 mg/kg. The brain-to-plasma ratios
were about 10% in both species. In mice, plasma levels after
20 mg/kg s.c. were comparable to 100 mg/kg p.o. Peak
plasma and brain levels are reached 1 h after dosing. Brain
concentration levels for mice, rats and dogs are given in
Table 1. Plasma protein binding amounted to approximately
90% across species and amounted to 89% in human plasma.
3.2 BL-6020/979 dose-dependently increases food intake
in healthy NMRI mice
Daytime food consumption was measured for the first
4 h after compound administration at various doses via
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subcutaneous and oral routes. The results showed an increase
in daytime food intake at doses of and above 50 mg/kg via the
oral route and 20 mg/kg via subcutaneous injection (Fig. 1).
Oral administration of BL-6020/979 increased daytime food
intake in a dose-dependent manner, resulting in a 3- to 5-fold
increase in the amount of food consumed over a 4 h period.
Noteworthy, both themagnitude of effect on food intake as well
as the peak plasma levels attained after 20 mg/kg s.c. and
100 mg/kg p.o. administration were comparable. Importantly,
the drug-induced feeding occurred in non-fasted animals
during the light phase, where, under normal (non-stressed)
conditions, food intake is low as seen in the vehicle group of
the present experiments.
3.3 The effects of BL-6020/979 on food intake and energy
expenditure are MC-4R mediated
Feeding and energy expenditure data was normalized to
body mass because MC-4R−/− mice are known to differ
from wild-type control mice in body mass and in baseline
feeding characteristics [31]. After daytime application,
there was a significant increase in food intake in wild-
type mice treated with 100 mg/kg BL-6020/979 p.o.
compared with vehicle-treated controls 4 h after applica-
tion. This effect was not observed in the MC-4R−/− mice.
Nighttime dosing led to similar results. Although the
BL-6020/979 treated groups of both genotypes did not
differ from vehicle controls of each genotype (ANOVA,
p=0.24), BL-6020/979 treated mice showed a tendency to
increase food intake in wild-type but not in MC-4R−/− mice
(Fig. 2A and B)
The expected overall lower VO2 value was observed in
MC-4R−/− animals relative to wild-type controls, therefore
the data were normalized to the values for vehicle-treated
mice of each genotype [33]. During the first 4 h post dosing
at nighttime, the 100 mg/kg BL-6020/979 p.o. treated wild-
type mice had a basal VO2 that was significantly lower than
the vehicle-treated wild-type group, whilst no such differ-
ence was observed in treated and untreated MC-4R−/− mice.
In contrast, application of the compound during daytime
did not yield any significant differences in wild-type or
MC-4R−/−mice (Fig. 2C and D).
In line with the results on the energy intake and
expenditure, body mass changed during the course of the
experiment. BL-6020/979 treated wild-type mice lost less
and gained more body mass after daytime and nighttime
application, respectively. In contrast, however, MC-4R−/−
mice treated with BL-6020/979 lost more body mass than
controls after daytime application, but after nighttime
application there was no difference between these groups
(Fig. 2E and F).
3.4 BL-6020/979 ameliorates cachexia in the murine C26
adenocarcinoma model
Daily oral administration of BL-6020/979 (p.o., 30 mg/kg)
consistently reduced signs of cachexia in three independent
experiments (Fig. 3). Data from each of these three separate
experiments were similar and, thus, were pooled for further
analysis. A tumor developed in all inoculated animals and
was palpable around day 4 after inoculation. Importantly,
tumor growth was not altered by treatment and final tumor
mass was similar in all groups, i.e., 0.99±0.05 g in the
30 mg/kg BL-6020/979 vs. 1.02±0.04 g in the vehicle
control group, confirming that no anti-tumor effects of the
compound confounded its effect on the cachexia.
Vehicle-treated mice started losing body mass around
days 10–12 after inoculation. This was ameliorated in the
BL-6020/979 treated group, and at the end of the
experiment the average body mass of the compound treated
mice was significantly higher than that of the vehicle-
treated tumor-bearing mice (Fig. 3A).
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Fig. 1 The effect of BL-6020/979 on 4 h light-phase food intake in
female mice. Food intake of female NMRI mice after a subcutaneous
or b oral application of BL-6020/979 at indicated doses. Animals were
housed in groups of three. The food intake (per cage) was recorded 4 h
post administration of compound whereby food intake was normalized
to 100 g body weight. Bars represent the mean±SEM cumulative food
intake per cage. All BL-6020/979 groups n=6 cages, and Vehicle
n=12 cages. Significance vs. vehicle in Dunnett’s post hoc test:*p<
0.05 ***p<0.001
Table 1 BL-6020/979 is orally bioavailable in mice, rats and dogs
and penetrates the brain
Mouse Rat Dog
Dose in mg/kg p.o. 50 50 10
Cplasma in nM 1269±404 2277±340 2426±1036
Cbrain in nM 110±26 151±27 n.d.
b/p ratio in % 12 8 n.d.
PPB in % 92 87 93
BL-6020/979 was given orally at indicated dose. N=3 per group,
mean±SD are given
b/p brain-to-plasma-ratio, n.d. not determined, PPB plasma protein
binding
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In addition to the effect on body mass, treatment with
30 mg/kg BL-6020/979 p.o. positively affected body compo-
sition whereby both fat and lean mass were significantly
increased compared to vehicle-treated tumor-bearing mice,
which showed a distinct loss of fat and lean body mass
compared to non-tumor-bearing mice (Fig. 3C and D).
Cachexia, defined as loss of more than 5% of body mass
in the course of the experiment, did not occur in all tumor-
bearing mice. However, cachexia was absent in 16 of 29
BL-6020/979-treated animals but only in 9 of the 29
vehicle-treated animals. Kaplan–Meier analysis of the onset
of cachexia (i.e., the day ≥5% body mass was lost) revealed
a significant beneficial effect of BL-6020/979 compared to
the vehicle-treated controls (p=0.04, Fig. 3B).
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Fig. 2 The effects of BL-6020/979 on food intake and energy expenditure
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On the gene expression level, and in line with the
effects on body composition and body weight, 30 mg/kg
BL-6020/979 p.o. prevented deregulation of genes
relevant for muscle atrophy, i.e., Atrogin-1 and PGC-1β
(Table 2). These genes are typically up-regulated (Atrogin-1)
or down- regulated (PGC-1β) during cachexia and other
muscle wasting pathologies.
Unexpectedly, there was no clear effect of BL-6020/979
on food intake in the last third (d10–d15) of the experiment,
when the cachexia was apparent. The total food consump-
tion of BL-6020/979 and vehicle-treated tumor-bearing
mice did not differ significantly in this period although a
difference in body mass was observed. However, there was
a trend in the expected direction with an increased food
intake in BL-6020/979 treated mice (14.5±0.5 g) compared
to vehicle-treated mice (13.3±0.7 g); both groups’ food
intake was lower (p<0.001) than that of non-tumor-bearing
mice (17.2±0.3 g).
3.5 BL-6020/979 has antidepressant-like effects in the rat
chronic mild stress model
As expected, sucrose consumption gradually decreased in
the vehicle-treated stressed animals but not in the non-
stressed during the baseline weeks before the rats were
treated (data not shown). Imipramine—a known antide-
pressant—reversed the effect of stress, i.e., the sucrose
intake of treated rats was significantly higher than in
vehicle-injected stressed rats and was indistinguishable in
rats from the control group starting at week 3 of the
experiment (Fig. 4A). Similar to imipramine, 10 mg/kg
BL-6020/979 p.o. produced significant treatment effects in
stressed rats but was inactive in non-stressed controls. This
positive effect was apparent only 1 week later than in the
imipramine-treated group. Of note, both imipramine-treated
groups—the stressed as well as the control group—gained
less body mass in the 5 weeks of the treatment period than
vehicle-treated controls (control, p<0.05; stressed, p<0.001),
while body mass gain in BL-6020/979-treated animals was
indistinguishable from vehicle-treated stressed and control
rats (control and stressed: n.s.; data not shown).
4 Discussion
Blockade of the MC-4R by an endogenous antagonist or
genetic deletion has previously been proven effective in
experimental animal models of cachexia [20]. Likewise
peptidic antagonists have been used, and subsequently the
development of more drug-like small molecules and even
antibodies against this target has been pursued by pharma-
ceutical companies and academic groups [19, 34–36].
Regarding the prevention of cachexia, the current data
strongly suggest that it is indeed the dual effect of increased
food intake and decreased energy expenditure which is key
to the beneficial features of this mode of action [17]. We
have demonstrated, that the novel, orally available, non-
peptidic small-molecule MC-4R antagonist BL-6020/979
was not only able to increase food intake and prevent
cancer cachexia like previous chemically related com-
pounds [23]. Overall, this promising candidate is clearly
superior to previously described earlier lead compounds
[23] from the same optimization program. Importantly, its
general pharmacological properties, tolerability and safety,
were markedly improved. In addition, it decreased energy
expenditure in healthy mice. BL-6020/979 displayed high
selectivity and low nanomolar affinity towards binding and
inhibition of the MC-4R. Consistent with its designated
mode of action, its pharmacological activity in vivo is
mediated selectively via the MC-4 receptor since BL-6020/
979 was without effect in mice lacking this receptor.
The MC-4R antagonist BL-6020/979 significantly
increased food intake during the day. A similar trend
towards an increase in food intake was detected at the
beginning of the night. Inversely, treatment with BL-6020/
979 efficiently reduced energy expenditure at night in
healthy wild-type animals. When given during the day, this
effect was not observed. This is likely the result of the
inactive state of the mice during the day which, typically
for nocturnal animals [37], reduces their basal level of
energy expenditure during the resting phase to a level that
cannot be lowered further. Conversely, food intake is
highest during the early night, where it might not be
possible to stimulate a further increase, and low during the
day, when application BL-6020/979 caused a significant
increase.
Previously, nonspecific blockade of the MC-4R through
intra-cerebroventricular application of the endogenous
ligand AgRP or SHU-9119 has been shown to be effective
in cancer-induced cachexia models [21, 38]. Similarly,
small-molecule MC-4R antagonists have been reported to
ameliorate cachexia in rodent models [39, 40] but none of
them have been reported to be moved towards clinical
development.
The completely non-peptidic small-molecule BL-6020/
979 is one of the first MC-4R antagonists that ameliorated
Table 2 The effects of 30 mg/kg BL-6020/979 p.o. on gene
expression in the C26 tumor model
Group Atrogin-1 PGC-1β
Vehicle 1.0 (0.9–1.2)*** 1.1 (0.8–1.2)***
Vehicle+tumor 20.1 (4.1–28.8) 0.2 (0.1–0.4)
30 mg/kg BL-6020/979+tumor 3.0 (1.4–19.4) 0.5 (0.2–0.6)***
Relative expression levels of Atrogin-1 and PGC-1β in gastrocnemius
muscle of mice. Median (interquartile range) are given (n=27–29/
group). Statistical difference in Dunn’s post hoc test vs. Vehicle+
tumor with ***p<0.001
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cancer cachexia after oral administration. BL-6020/979
showed beneficial effects on body mass and composition
in the C26 murine cachexia model as had been shown
previously for earlier lead compounds from the same and
from a chemically distinct series [23]. Probably as a
consequence of its beneficial effect on lean mass,
BL-6020/979 also showed effects at the gene expression
level in the gastrocnemius. The up-regulation of the
ubiquitin ligase Atrogin-1, which has been shown to be
essential for muscle degeneration [41], was attenuated.
Similarly, the decrease in PGC-1β that is typical for muscle
degeneration [42] was prevented (Table 2).
It might be a benefit of the dual effect of MC-4R
blockade on food intake and energy expenditure [17] that
although no significant effect of BL-6020/979 on food
intake could be observed, compound-treated animals did
lose significantly less body mass indicating treatment
success. This lack of an effect on food intake might be
due to the high variability in daily food intake that we
observed in our experiments. If averaged over 5 days, there
was a trend towards an increased food intake in BL-6020/
979 treated mice. In addition, and based on the data from
healthy animals (Fig. 2) and the effects of MC-4R blockade
described previously [17], we speculate that this positive
outcome might have been due to the lowered energy
expenditure of the treated animals.
Important for further development, BL-6020/979 is the
first MC-4R antagonist with an overall favorable pharma-
cological profile. In vitro, a low nanomolar affinity at the
targeted MC-4R and high selectivity against most closely
related melanocortin receptors 3, 5, and 1 was evident.
Moreover, at a concentration of 10 μM, the compound
exhibited very little off-target activities confirming its
excellent selectivity in a standard panel of over 100
receptors, ion channels, transporters, and enzymes. Of note
was that BL-6020/979 has a single digit micromolar affinity
for the delayed rectifier current-producing K+ channel
encoded by hERG. The blockade of this channel is often
associated with QT prolongation and torsade des pointes
[43]. Retrospective data on marketed drugs on prolonged
QT effects have shown that a safety margin of the IKr/hERG
IC50 divided by Cmax of free drug in plasma concentration
of >30 up to ∼45-fold can be considered uncritical for
further development [44, 45]. Considering the compound’s
plasma protein binding of approximately 90% and an
efficacious dose in mice of 50 mg/kg p.o. in the food
intake assay in healthy mice, the estimated peak plasma
concentration of free drug in vivo amounts to approximately
100 nM. Thus, BL-6020/979 fulfills this consensus
industry standard and has a calculated ∼50-fold safety
margin for hERG inhibition. Based on this as well as
published literature, it is therefore not anticipated that
BL-6020/979 will have an effect on QT prolongation in
vivo [45].
Moreover, the toxicological profile of BL-6020/979 (in
in vitro toxicity and in vivo acute and 7-day repeated dose
toxicity studies) in relation to its pharmacological effects
supports the further development of BL-6020/979. These
data are further endorsed by an in vivo genotoxicity study
which did not find any indication of a clastogenic and/or
aneugenic potential of BL-6020/979.
In addition to chemotherapy, most cancer patients
already receive a cocktail of drugs, e.g., analgesics,
antiemetics, and antidepressants [46, 47]. Thus, a potential
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cachexia drug should exhibit a low potential for induction
or inhibition of cytochromes involved in drug metabolism
of the co-medications. Indeed, BL-6020/979 did not show
any critical inhibitory activity in the human CYP isoforms
tested. CYP3A4 induction was assessed in human hepato-
cytes according to the draft FDA guidance to industry for
drug interaction studies. Based on the obtained results (data
not shown) BL-6020/979 is not considered to be an inducer
of CYP3A4. Taken together, the data indicate a low
potential for inhibition—or induction—based drug–drug
interactions.
As stated above and like in other chronic diseases in
which cachexia develops, cancer is typically accompanied
by a whole plethora of co-morbidities treated with a
cocktail of various drugs. We were interested to assess
whether BL-6020/979 could provide a beneficial co-effect
in any of these. For example, depression is a common
problem in cancer patients [48]. Interestingly, MC-4R
antagonism has been previously investigated as a potential
mode of action in the treatment of depression due to
anxiolytic and antidepressant-like effects in animal models
[22]. We have chosen the chronic mild stress paradigm
because of its excellent construct and predictive validity
[49] and could demonstrate that BL-6020/979 exhibits
antidepressant-like effects comparable to imipramine, a
standard treatment in cancer-related depression [50].
Similarly, and also highly relevant for cancer patients,
MC-4R antagonism has been shown to be effective in
models of neuropathic pain as an analgesic [51]. Equally
interesting, a modulating effect on opioid tolerance as has
been shown to be mediated by this mechanism [52].
Therefore, BL-6020/979 may open an option to treat not
only cachexia itself but also accompanying symptoms,
typical of the clinical presentation of the disease. Further
studies elucidating these possible additional effects of
BL-6020/979 seem warranted.
Cachexia is not only part of the clinical manifestation of
many cancer types but also of other diseases like chronic
kidney disease [53], liver failure [54], chronic obstructive
pulmonary disease (COPD) [55], chronic heart failure [56],
and AIDS [57]. Based on its mechanism, MC-4R blockade
might be beneficial in the treatment of all of the above
mentioned causes of cachexia. It has been suggested that
hypothalamic energy homeostasis is disturbed in a similar
way in all these diseases by inflammation of key brain
regions [6]. It has been shown that MC-4R blockade can
ameliorate or even prevent the occurrence of cachexia for
most of these underlying pathologies. It remains an
interesting question to be answered in future studies
whether BL-6020/979 could prove useful in any of these
indications.
In summary, melanocortin-4 receptor antagonism in
general seems to represent an exciting mode of action not
only for the treatment of cancer-induced cachexia but also
other forms of wasting disorders [6, 58]. Although several
pharmaceutical companies and academic groups worked on
the development of small molecules and even antibodies
against this target, no treatment is currently available for
cachexia patients or even in ongoing clinical testing [34,
35, 59], potentially underscoring the complexity of the MC-
4 receptor and the highly challenging medicinal chemistry
required, not only to address it, but in particular to identify
antagonist compounds with a balanced overall pharmacolog-
ical and safety profile. In fact, BL-6020/979 is the result of an
extensive lead optimization program and fulfills these require-
ments as the first orally available completely non-peptidic,
small-molecule MC-4R antagonist. Its overall profile qualifies
this novel chemical entity for development towards treatment
of human patients. Consequently, BL-6020/979 is currently in
late stage pre-clinical development as a first-in-class treatment
option for cancer cachexia. This opens up the long-awaited
opportunity to validate the benefits of treating cachexia with
MC-4R antagonists in human patients.
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